Characterization of a serum protein pattern from NSCLC patients treated with Gefitinib

The purpose of this study was to evaluate the efficacy of a protein-based pattern in serum previously determined by MALDI-TOF-MS (Matrix Assisted Laser Desorption Ionization-Time of Flight) and considered potentially useful for prediction of clinical outcome of EGFR (epidermal growth factor receptor...

Full description

Saved in:
Bibliographic Details
Published in:Clinical biochemistry 2011-07, Vol.44 (10), p.936-940
Main Authors: Garrisi, V.M., Bongarzone, I., Mangia, A., Cremona, M., De Bortoli, M., Vaghi, E., Galetta, D., Pastorino, U., Quaranta, M., Abbate, I., Paradiso, A.
Format: Article
Language:English
Subjects:
Aged
Algorithms
Antineoplastic agents
Biological and medical sciences
Biomarkers
Blood Proteins - metabolism
Carcinoma, Non-Small-Cell Lung - blood
Carcinoma, Non-Small-Cell Lung - drug therapy
Carcinoma, Non-Small-Cell Lung - pathology
Case-Control Studies
Chemotherapy
Disease Progression
Electrophoresis, Polyacrylamide Gel
Enzyme-Linked Immunosorbent Assay
Female
Humans
Lung Neoplasms - blood
Lung Neoplasms - drug therapy
Lung Neoplasms - pathology
Male
Medical sciences
Middle Aged
NSCLC
Pharmacology. Drug treatments
Pneumology
Protein Kinase Inhibitors - therapeutic use
Proteomics
Quinazolines - therapeutic use
SAA
SELDI-TOF
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
Tumors of the respiratory system and mediastinum
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The purpose of this study was to evaluate the efficacy of a protein-based pattern in serum previously determined by MALDI-TOF-MS (Matrix Assisted Laser Desorption Ionization-Time of Flight) and considered potentially useful for prediction of clinical outcome of EGFR (epidermal growth factor receptor) TKIs (tyrosine kinase inhibitors) treated patients. We generated SELDI-TOF (Surface Enhanced Laser Desorption Ionization-Time of Flight) spectra in sera of 11 advanced NSCLC treated with Gefitinib. We detected the clusters with m/ z 5843, 11 445, 11 529, 11 685, 11 759 and 11 903 which were previously reported to be potential predictors of response to Gefitinib treatment. Four cluster peaks with m/ z 5843, 11 445, 11 529, 11 685 corresponded to SAA (serum amyloid A) protein on the basis on their calculated molecular weight, peptide fingerprinting and antibodies recognition. We confirm that several proteins already reported were isoforms of SAA but further studies are in development in order to evaluate the predictive value of such algorithm.
ISSN:0009-9120
1873-2933
DOI:10.1016/j.clinbiochem.2011.04.013